How Often Is Invasive Cancer Found After a DCIS Biopsy?
At a Glance
Among people diagnosed with DCIS by needle biopsy who go on to surgery, invasive breast cancer is found in about 1 in 4 cases on average. The personal chance varies with imaging findings, biopsy method, lesion features, and how studies define invasion.
Bottom Line:
Among people diagnosed with ductal carcinoma in situ (DCIS) by a needle biopsy who undergo surgery, studies estimate that an invasive focus is found in roughly 1 in 4 cases (about 25.8%) [1]. However, this is a group average. Depending on your imaging results, the type of biopsy you had, and how the study defines “invasive,” the rates reported by individual clinics range from 8% to 36% [2][3]. Your personal likelihood may be much lower or higher.
What An Upgrade Means (And Does Not Mean)
A core needle biopsy samples only a small part of a suspicious area. If surgery later removes the entire area and the final pathology report shows invasive breast cancer, this change in diagnosis is called an upgrade.
- It means cancer cells have grown through the milk duct wall into the immediate nearby breast tissue [4].
- It does not mean the cancer has spread to lymph nodes or distant organs (metastasized) [5].
- It does not mean the biopsy caused the cancer to spread. It simply means the needle didn’t capture the invasive portion of the lesion [6].
- It does not mean a mistake was made. It reflects the limits of sampling a small area [7].
Why Do Estimates Vary So Much?
The likelihood of an upgrade depends heavily on how the biopsy was performed and how data is categorized [6]:
- Biopsy Method: A vacuum-assisted breast biopsy (VABB) uses gentle suction to pull more tissue into the needle. Studies show lower upgrade rates with VABB compared to standard core needle biopsy (CNB) [8]. However, VABB does not eliminate the possibility of an upgrade; your risk still depends on the lesion and how much tissue was removed [9].
- Amount of Tissue Sampled: Removing more tissue cores gives pathologists a more complete picture, reducing the chance that an invasive area is left behind [7].
- Microinvasion: Some studies group larger invasive cancers together with microinvasion (an invasive area measuring 1 millimeter or less) [4]. When studies separate the two, the rate of finding invasive cancer larger than 1 mm is lower [7].
What Factors Increase the Risk of an Upgrade?
Features on your imaging or biopsy can make an upgrade more likely. These are associations, not guarantees:
- A visible or palpable mass: If you can physically feel a lump, or if a distinct mass is visible on an ultrasound or MRI, the risk of finding invasive cancer is higher than if your imaging only showed calcifications [10][11].
- Larger size or spread: DCIS lesions that are larger (some studies use a 2-centimeter cutoff) or are multicentric (spread across multiple separate areas of the breast) carry a higher upgrade risk [12][13]. Note that the size on imaging may not perfectly match the final pathology size.
- High-grade cells or necrosis: If the biopsy shows high nuclear grade (more abnormal-looking cells associated with aggressive behavior) or comedonecrosis (areas of dead cells within the milk ducts), an invasive component is more likely [14][15].
How an Upgrade Could Change Your Treatment Plan
Because an upgrade is usually discovered days after surgery when the final pathology report is ready, your care team may need to adjust your ongoing plan [4].
- Sentinel Lymph Node Biopsy (SLNB): An SLNB checks the first draining lymph nodes for cancer cells. For pure DCIS treated with a lumpectomy (breast-conserving surgery), SLNB is generally omitted because non-invasive cells rarely spread [5]. However, if your doctor suspects a high risk of an upgrade, they may consider an SLNB during your lumpectomy to avoid a second surgery if invasive cancer is found [16]. For patients having a mastectomy, SLNB is usually recommended during the initial surgery because removing the breast makes it difficult to map the lymph nodes later [5].
- Surgical Margins: The goal of surgery is to remove the disease with a rim of healthy tissue (a margin). For pure DCIS treated with a lumpectomy and whole-breast radiation, guidelines recommend a clear margin of at least 2 millimeters [17]. If invasive cancer is found, the standard for the invasive portion is typically “no ink on tumor” (meaning no cancer cells touch the very edge of the removed tissue) [18]. Having a margin closer than 2 mm does not automatically mean you need a second surgery; the decision is individualized based on the invasive and in-situ components and your radiation plan [18].
- Additional Treatments: An upgrade does not automatically mean you will need chemotherapy. Your cancer stage will be updated based on the size of the invasive tumor, your lymph node status, and biomarkers like hormone receptors (ER/PR) and HER2 (a tumor protein) [19]. Depending on these results, your overall health, and sometimes genomic testing, your doctor may discuss treatments to reduce recurrence risk. This can include radiation, endocrine therapy (hormone-blocking pills), HER2-targeted therapy, or chemotherapy [4][19].
Common questions in this guide
How often is invasive breast cancer found after a needle biopsy shows DCIS?
What does it mean if DCIS is upgraded to invasive breast cancer?
Which findings make an upgrade from DCIS more likely?
Does a vacuum-assisted biopsy lower the chance that invasive cancer will be found at surgery?
Could an upgrade change whether I need lymph node surgery?
If invasive cancer is found, does that mean I will need chemotherapy?
Related questions
Get notified when new evidence is published on ductal breast carcinoma in situ.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data.
Chiu CW, Chang LC, Su CM, et al.
Surgical oncology 2022; (45()):101880 doi:10.1016/j.suronc.2022.101880.
PMID: 36332555 - 2
Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB, Reisenbichler ES, Roland L, et al.
Archives of pathology & laboratory medicine 2018; (142(9)):1120-1126 doi:10.5858/arpa.2017-0268-OA.
PMID: 29582675 - 3
Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ.
Pang J, Yan Z, Tan QT, et al.
Clinical breast cancer 2024; (24(4)):363-367 doi:10.1016/j.clbc.2024.02.002.
PMID: 38458843 - 4
Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review.
Song G, Zhang Y
Chronic diseases and translational medicine 2023; (9(1)):5-13 doi:10.1002/cdt3.53.
PMID: 36926252 - 5
The Use of Sentinel Lymph Node Biopsy in Patients Undergoing Mastectomy for DCIS.
Johnson MK, Cortina CS, Aldakkak M, et al.
Clinical breast cancer 2024; (24(7)):611-619 doi:10.1016/j.clbc.2024.07.003.
PMID: 39127597 - 6
Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.
Mannu GS, Groen EJ, Wang Z, et al.
Breast cancer research and treatment 2019; (178(2)):409-418 doi:10.1007/s10549-019-05362-1.
PMID: 31388937 - 7
Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.
Marabi M, Li Y, Aphivatanasiri C, et al.
Histopathology 2026; (89(1)):122-135 doi:10.1111/his.70143.
PMID: 41905345 - 8
Vacuum-assisted breast biopsy vs core needle biopsy: a systematic review and meta-analysis.
Sharma N, Theis S, Vogelmann T, Pijnappel R
European radiology 2026; (36(6)):4449-4466 doi:10.1007/s00330-025-12299-1.
PMID: 41553473 - 9
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer.
Park KW, Kim SW, Han H, et al.
NPJ breast cancer 2022; (8(1)):8 doi:10.1038/s41523-021-00364-z.
PMID: 35031626 - 10
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K, Masuda N, Hayashi N, et al.
Breast cancer (Tokyo, Japan) 2021; (28(4)):896-903 doi:10.1007/s12282-021-01225-0.
PMID: 33599914 - 11
The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.
Yoon GY, Choi WJ, Cha JH, et al.
BMC medical imaging 2020; (20(1)):95 doi:10.1186/s12880-020-00494-z.
PMID: 32787871 - 12
A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease.
Jakub JW, Murphy BL, Gonzalez AB, et al.
Annals of surgical oncology 2017; (24(10)):2915-2924 doi:10.1245/s10434-017-5927-y.
PMID: 28766196 - 13
Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS).
Price A, Schnabel F, Chun J, et al.
The breast journal 2020; (26(5)):931-936 doi:10.1111/tbj.13737.
PMID: 31957944 - 14
Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
Marques LC, Marta GN, de Andrade JZ, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(7)):1152-1155 doi:10.1016/j.ejso.2019.01.015.
PMID: 30665684 - 15
Predictive Histopathological Markers for Upstaging to Invasive Carcinoma after a Biopsy Diagnosis of Ductal Carcinoma in situ of the Breast: A Hypothesis-Generating Systematic Review.
Riggi JAM, Kassem I, Galant C, et al.
Pathobiology : journal of immunopathology, molecular and cellular biology 2026; (93(1)):34-47 doi:10.1159/000547335.
PMID: 40716433 - 16
Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM, Goorts B, Klinkert M, et al.
Breast cancer research and treatment 2016; (156(3)):517-525 doi:10.1007/s10549-016-3783-2.
PMID: 27083179 - 17
Prognostic impact of close margins on Loco-regional recurrence in ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy.
Kang J, Lee S, Jung S, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2026; (52(8)):111906 doi:10.1016/j.ejso.2026.111906.
PMID: 42229166 - 18
Margins in breast cancer: How much is enough?
Pilewskie M, Morrow M
Cancer 2018; (124(7)):1335-1341 doi:10.1002/cncr.31221.
PMID: 29338088 - 19
Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in Breast Carcinoma.
Naimi A, Mohaghegh N
Iranian journal of pathology 2024; (19(3)):318-325 doi:10.30699/IJP.2024.2025907.3285.
PMID: 39687455
This page is for informational purposes only and does not constitute medical advice. Your breast surgeon and pathology team can interpret your imaging, biopsy, and final surgical results and discuss your personal options.